Literature DB >> 35635433

Polymyalgia Rheumatica.

Miriam Giovanna Colombo1, Anna-Jasmin Wetzel, Hannah Haumann, Simon Dally, Gudula Kirtschig, Stefanie Joos.   

Abstract

BACKGROUND: Polymyalgia rheumatica (PMR) is among the most common inflammatory rheumatic diseases in older adults. Presumed risk factors include female sex, previous infections, and genetic factors. No epidemiological data on PMR in Germany have been available until now.
METHODS: This review is based on publications retrieved by a selective literature search in PubMed. Moreover, the administrative incidence and prevalence of PMR in the years 2011-2019 was determined from data of the AOK Baden-Württemberg statutory health insurance carrier for insurees aged 40 and older. In addition, we quantified the number of consultations with physicians involved in the diagnosis.
RESULTS: The annual age- and sex-standardized incidence and prevalence of PMR from 2011 to 2019 were 18.6/100 000 persons and 138.8/100 000 persons, respectively. The incidence was higher in women than in men (21.8/100 000 vs. 12.8/100 000 persons per year). 60% of the cases were diagnosed in primary care practices. The treatment of PMR with orally administered glucocorticoids usually results in a treatment response within a few days to weeks. Approximately 43% of patients experience recurrent symptoms within a year, requiring adjustment of the glucocorticoid dose. For older patients with impaired physical ability, additional non-pharmacological treatment with exercise programs plays an important role.
CONCLUSION: PMR usually takes an uncomplicated course under treatment and can be managed in primary care, but these patients are often multimorbid and require frequent follow-up. Along with research on the etiology of the disease, further studies are needed to identify the risk factors for a chronic course and to evaluate the potential effects of non-pharmacological measures.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35635433      PMCID: PMC9533703          DOI: 10.3238/arztebl.m2022.0218

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   8.251


  32 in total

1.  Utilisation and costs of investigations, and accuracy of diagnosis of polymyalgia rheumatica by family physicians.

Authors:  S Bahlas; C Ramos-Remus; P Davis
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

2.  The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.

Authors:  Cynthia S Crowson; Eric L Matteson; Elena Myasoedova; Clement J Michet; Floranne C Ernste; Kenneth J Warrington; John M Davis; Gene G Hunder; Terry M Therneau; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2011-03

3.  Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis.

Authors:  Ciro Manzo; Marcin Milchert; Maria Natale; Marek Brzosko
Journal:  Rheumatology (Oxford)       Date:  2019-05-01       Impact factor: 7.580

Review 4.  [S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations].

Authors:  F Buttgereit; T Brabant; H Dinges; I Hiemer; M Kaplani; U Kiltz; D Kyburz; A Reißhauer; M Schneider; C Weseloh; C Dejaco
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

5.  Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.

Authors:  Katinka Albrecht; Dörte Huscher; Frank Buttgereit; Martin Aringer; Guido Hoese; Wolfgang Ochs; Katja Thiele; Angela Zink
Journal:  Rheumatol Int       Date:  2017-11-09       Impact factor: 2.631

Review 6.  The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle.

Authors:  Guillermo Carvajal Alegria; Sara Boukhlal; Divi Cornec; Valérie Devauchelle-Pensec
Journal:  Autoimmun Rev       Date:  2020-09-15       Impact factor: 9.754

7.  Epidemiology of Polymyalgia Rheumatica 2000-2014 and Examination of Incidence and Survival Trends Over 45 Years: A Population-Based Study.

Authors:  Shafay Raheel; Izzat Shbeeb; Cynthia S Crowson; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-07-10       Impact factor: 4.794

8.  Polymyalgia rheumatica prevalence in a population-based sample.

Authors:  S Bernatsky; L Joseph; C A Pineau; P Belisle; L Lix; D Banerjee; A E Clarke
Journal:  Arthritis Rheum       Date:  2009-09-15

9.  Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection.

Authors:  P Elling; A T Olsson; H Elling
Journal:  J Rheumatol       Date:  1996-01       Impact factor: 4.666

Review 10.  Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.

Authors:  Dario Camellino; Andrea Giusti; Giuseppe Girasole; Gerolamo Bianchi; Christian Dejaco
Journal:  Drugs Aging       Date:  2019-11       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.